

Depemokimab for treating chronic rhinosinusitis with nasal polyps in adults (terminated appraisal)

Technology appraisal guidance

Published: 22 January 2026

www.nice.org.uk/guidance/ta1123

Contents

Advice.....	3
Information.....	3

Advice

NICE is unable to make a recommendation about the use in the NHS of depemokimab for treating chronic rhinosinusitis with nasal polyps in adults. This is because GlaxoSmithKline has not made an evidence submission for the appraisal.

Information

If NHS organisations wish to consider depemokimab for this indication, they should follow the advice on rational local decision making in the [NHS Constitution for England](#) and the [NHS Commissioning Board and Clinical Commissioning Groups \(Responsibilities and Standing Rules\) Regulations 2012](#). This outlines the approach that should be taken when there is no NICE guidance.

NICE will review the position if the company decides that it wants to make an evidence submission.

ISBN: 978-1-4731-8424-4